Accès gratuit
Numéro
Thérapie
Volume 62, Numéro 3, Mai-Juin 2007
XXIIes Rencontres Nationales de Pharmacologie Clinique, Giens 7-10 octobre 2006
Page(s) 241 - 244
Section Pharmacovigilance/Pharmacovigilance
DOI https://doi.org/10.2515/therapie:2007048
Publié en ligne 6 septembre 2007
  1. Code de la santé publique. Art L-5111-1
  2. Directive 65/65/CEE du Conseil, du 26 janvier 1965, concernant le rapprochement des dispositions législatives, réglementaires et administratives, relatives aux spécialités pharmaceutiques
  3. USA/FDA. CFR (Code of Federal Regulation) Title 21: Food and drugs. Chapter 1: Food and Drug administration. Subchapter F: Biologics. Part 600: Biological products : General
  4. Canada / PPHB. Guidelines for reporting adverse events associated with vaccine products. Canada Communicable Disease Report. Volume 26 – S1 – February 2000
  5. Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/382702/2006, October 2006
  6. Concept paper for a guideline on the conduct of pharmacovigilance for vaccines. PhVWP/372004/2005 - October 2005
  7. www.ecdc.eu.int/Health_topics/VI/VI_newsletter.html
  8. Anon. Calendrier vaccinal 2006 ; avis du Conseil Supérieur d'Hygiène publique de France. BEH N° 2930/2006
  9. Laribière A, Miremont-Salamé G, Reyre H, et al. Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol. 2005; 61: 907-11 [CrossRef] [PubMed]
  10. Bagheri H, Gony M, Montastruc JL. A propos d'une campagne de vaccination contre la méningite C dans les Hautes-Pyrénées : réflexions de pharmacovigilance. Therapie 2005; 60: 287-94 [CrossRef] [EDP Sciences] [PubMed]
  11. Anon. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. PPR weekly 2005; 54: 893-7
  12. Metlay JP, Fishman NO, Joffe M, et al. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006; 24: 468-75 [CrossRef] [PubMed]
  13. Law DKS, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.P19). J Clin Microbiol 2006; 44: 2743-9 [CrossRef] [PubMed]